Authors : Harani S.; Pavithra V.

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/z2eck3ev

Scribd : https://tinyurl.com/2ayu54vt

DOI : https://doi.org/10.38124/ijisrt/25aug909

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Alzheimer’s disease (AD) is a progressive neurological disorder and the leading cause of dementia in older adults, characterized by memory loss, cognitive dysfunction, and behavioural disturbances. The disease is associated with the abnormal buildup of beta-amyloid plaques and hyperphosphorylated tau tangles, along with oxidative stress, mitochondrial impairment, neurotransmitter imbalances, and neuroinflammation. Genetic factors, particularly the presence of the APOE- ε4 allele, further increase disease susceptibility. Despite the availability of FDA-approved drugs targeting cholinergic and glutamatergic systems, current treatments provide only symptomatic relief and do not halt disease progression. One of the major challenges in AD therapy is the limited ability of drugs to cross the blood-brain barrier (BBB). Nanotechnology presents a promising alternative by enabling the targeted delivery of therapeutic agents across the BBB with improved bioavailability and minimal systemic side effects. This review discusses the underlying mechanisms of AD and recent advancements in Nano formulations such as liposomes, polymeric nanoparticles, dendrimers, and lipid-based carriers for delivering anti-amyloid, anti-tau, and antioxidant therapies. These innovative approaches may offer new hope in managing and potentially modifying the course of Alzheimer’s disease.

Keywords : Alzheimer’s, Liposomes, Nanosomes, Nanomedicine.

References :

1. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2012 Aug 1;2(8):a006239.
2. Abdelmeguid NE, Khalil MI, Elhabet R, Sultan AS, Salam SA. Combination of docosahexaenoic acid and Ginko biloba extract improves cognitive function and hippocampal tissue damages in a mouse model of Alzheimer’s disease. Journal of Chemical Neuroanatomy. 2021 Oct 1;116:101995.
3. Hawiset T, Sriraksa N, Kamsrijai U, Praman S, Inkaew P. Neuroprotective effect of Tiliacora triandra (Colebr.) Diels leaf extract on scopolamine-induced memory impairment in rats. Heliyon. 2023 Dec 1;9(12).
4. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free radical biology and medicine. 1997 Jan 1;23(1):134-47.
5. Hafez HS, Ghareeb DA, Saleh SR, Abady MM, El Demellawy MA, Hussien H, Abdel-Monem N. Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats. Psychopharmacology. 2017 Oct;234: 3037-53.
6. Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of today (Barcelona, Spain: 1998). 2003 Jan 1;39(1):75-83.
7. Dewachter I, Van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Experimental gerontology. 2000 Sep 1;35(6-7):831-41.
8. Dá Mesquita S, Ferreira AC, Sousa JC, Correia-Neves M, Sousa N, Marques F. Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience & Biobehavioral Reviews. 2016 Sep 1;68:547-62.
9. Xia W, Han E. Etiological factors of Alzheimer disease and recent advances of its treatment. Neural Regeneration Research. 2007 Feb 1;2(2):107-11.
10. Unnisa A, Greig NH, Kamal MA. Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease. Current Medicinal Chemistry. 2023 Jan 1;30(3):255-70.
11. Patel V, Rajput MS, Patel A, Patel M, Patel R. Nanocrystals: a new herald for the management of Alzheimer’s disease. Journal of Dispersion Science and Technology. 2024 Oct 1:1-4.
12. Voigt N, Henrich-Noack P, Kockentiedt S, Hintz W, Tomas J, Sabel BA. Surfactants, not size or zeta-potential influence blood–brain barrier passage of polymeric nanoparticles. European Journal of pharmaceutics and Biopharmaceutics. 2014 May 1;87(1):19-29.
13. Panghal A, Flora SJ. Nanotechnology in the diagnostic and therapy for Alzheimer's disease. Biochimica et Biophysica Acta (BBA)-General Subjects. 2024 Jan 6:130559.
14. Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer's disease: an update. Annals of neurosciences. 2017 May 5;24(1):46-54.
15. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in molecular medicine. 2009 Mar 1;15(3):112-9.
16. Wang Y, Mandelkow E. Tau in physiology and pathology. Nature reviews neuroscience. 2016 Jan;17(1):22-35.
17. Marucci G, Buccioni M, Dal Ben D, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021 Jun 1;190:108352.
18. Singla S, Piplani P. Coumarin derivatives as potential inhibitors of acetylcholinesterase: Synthesis, molecular docking and biological studies. Bioorganic & Medicinal Chemistry. 2016 Oct 1;24(19):4587-99.
19. Rai S, Singh VK, Ahmad I, Agrawal M, Singh RK. Design, synthesis, molecular docking, DFT analysis, dynamics simulation and cytotoxicity evaluation of coumarin derivatives as acetylcholinesterase (AChE) inhibitors against alzheimer's disease. Journal of Molecular Structure. 2025 Jan 13:141436.
20. Van Giau V, An SS, Hulme JP. Mitochondrial therapeutic interventions in Alzheimer’s disease. Journal of the neurological sciences. 2018 Dec 15;395:62-70.
21. Swerdlow RH. Pathogenesis of Alzheimer’s disease. Clinical interventions in aging. 2007 Jan 1;2(3):347-59.
22. Uddin MS, Kabir MT, Al Mamun A, Abdel-Daim MM, Barreto GE, Ashraf GM. APOE and Alzheimer’s disease: evidence mounts that targeting APOE4 may combat Alzheimer’s pathogenesis. Molecular neurobiology. 2019 Apr;56(4):2450-65.
23. Zhang L, Hong H. Genomic discoveries and personalized medicine in neurological diseases. Pharmaceutics. 2015 Dec 7;7(4):542-53.
24. Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annual review of genomics and human genetics. 2000 Sep;1(1):507-37.
25. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-67.
26. Chauhan B, Patel S, Prajapati BG, Singh S. Drug delivery for Alzheimer's disease using nanotechnology: Challenges and advancements. InAlzheimer's Disease and Advanced Drug Delivery Strategies 2024 Jan 1 (pp. 361-371). Academic Press.
27. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ. Levels of Soluble Apolipoprotein E/Amyloid-β (Aβ) Complex Are Reduced and Oligomeric Aβ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*[S]. Journal of Biological Chemistry. 2013 Feb 22;288(8):5914-26.
28. Skoog I. and Gustafson D., Update on hypertension and Alzheimer′s disease, Neurology Research. (2006) 28, no. 6, 605–611.
29. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Disease & Associated Disorders. 2004 Oct 1;18(4):208-13.
30. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, Humala N, Thomas S, Martinez-Martin P, Pasinetti GM. Role of Hypertension in Aggravating Aβ Neuropathology of AD Type and Tau‐MediatedMotor Impairment. Cardiovascular psychiatry and neurology. 2009;2009(1):107286.
31. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology. 2009 May 19;72(20):1720-6.
32. Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, Gorantla S, Bronich TK, Edagwa B, Gendelman HE. Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews. 2019 Aug 1;148:252-89.
33. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy. 2014 Aug;6:1-7.
34. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Current pharmaceutical design. 2004 May 1;10(12):1355-63.
35. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC. The blood-brain barrier: an engineering perspective. Frontiers in neuroengineering. 2013 Aug 30;6:7.
36. Silva GA. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC neuroscience. 2008 Dec 10;9.
37. Silva GA. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC neuroscience. 2008 Dec 10;9(Suppl 3):S4.
38. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. International journal of nanomedicine. 2014 Feb 7:795-811.
39. Spuch C, Saida O, Navarro C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent patents on drug delivery & formulation. 2012 Apr 1;6(1):2-18.
40. Nguyen TT, Vo TK, Vo GV. Therapeutic strategies and nano-drug delivery applications in management of aging Alzheimer’s disease. Reviews on New Drug Targets in Age-Related Disorders: Part II. 2021:183-98.
41. Naqvi S, Panghal A, Flora SJ. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Frontiers in neuroscience. 2020 Jun 9;14:494.
42. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015 Aug 1;52:1-8.
43. Liu Z, Gao X, Kang T, Jiang M, Miao D, Gu G, Hu Q, Song Q, Yao L, Tu Y, Chen H. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjugate chemistry. 2013 Jun 19;24(6):997-1007.
44. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, Salmona M, Nicotra F, Gobbi M, Antimisiaris SG. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials. 2011 Feb 1;32(6):1635-45.
45. Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS one. 2012 Mar 5;7(3):e32616.
46. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M, Kumar S. Protective effects of Indian spice curcumin against amyloid-β in Alzheimer’s disease. Journal of Alzheimer’s Disease. 2018 Jan 9;61(3):843-66.
47. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience. 2001 Nov 1;21(21):8370-7.
48. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease. 2007 Jan 1:197-212.
49. Genchi G, Lauria G, Catalano A, Carocci A, Sinicropi MS. Neuroprotective effects of curcumin in neurodegenerative diseases. Foods. 2024 Jun 5;13(11):1774.
50. Ghalandari B, Asadollahi K, Shakerizadeh A, Komeili A, Riazi G, Kamrava SK, Attaran N. Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy. Journal of Photochemistry and Photobiology B: Biology. 2019 Mar 1;192:131-40.
51. Sonawane SK, Ahmad A, Chinnathambi S. Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s disease. ACS omega. 2019 Jul 29;4(7):12833-40.
52. Conti E, Gregori M, Radice I, Da Re F, Grana D, Re F, Salvati E, Masserini M, Ferrarese C, Zoia CP, Tremolizzo L. Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease. Neurochemistry international. 2017 Sep 1;108:60-5.
53. Kim MJ, Rehman SU, Amin FU, Kim MO. Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aβ1-42-induced neuroinflammation and neurodegeneration via the NF-KB/JNK/GSK3β signaling pathway. Nanomedicine: Nanotechnology, Biology and Medicine. 2017 Nov 1;13(8):2533-44.
54. Li H, Luo Y, Derreumaux P, Wei G. Carbon nanotube inhibits the formation of β-sheet-rich oligomers of the Alzheimer's amyloid-β (16-22) peptide. Biophysical journal. 2011 Nov 2;101(9):2267-76.
55.  Sorokina SA, Stroylova YY, Shifrina ZB, Muronetz VI. Disruption of amyloid prion protein aggregates by cationic pyridylphenylene dendrimers. Macromolecular bioscience. 2016 Feb;16(2):266-75.
56. Mirsadeghi S, Shanehsazzadeh S, Atyabi F, Dinarvand R. Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid beta fibrillation process. Materials Science and Engineering: C. 2016 Feb 1;59:390-7.              
57. Zhao L, Wu C, Lin K, Chang J. The effect of poly (lactic-co-glycolic acid)(PLGA) coating on the mechanical, biodegradable, bioactive properties and drug release of porous calcium silicate scaffolds. Bio-Medical Materials and Engineering. 2012 Jan 1;22(5):289-300.
58. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010 Feb 1;31(5):908-15.
59. Picone P, Bondi ML, Picone P, Bondi ML, Montana G, Bruno A, Pitarresi G, Giammona G, Di Carlo M. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles. Free Radical Research. 2009 Jan 1;43(11):1133-45.
60. Sivasankarapillai VS, Jose J, Shanavas MS, Marathakam A, Uddin MS, Mathew B. Silicon quantum dots: Promising theranostic probes for the future. Current drug targets. 2019 Sep 1;20(12):1255-63.
61. Li M, Zhao C, Duan T, Ren J, Qu X. New insights into Alzheimer's disease amyloid inhibition: Nanosized metallo‐supramolecular complexes suppress Aβ‐induced biosynthesis of heme and iron uptake in PC12 cells. Advanced healthcare materials. 2014 Jun;3(6):832-6.
62. Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European journal of medicinal chemistry. 2014 Jun 10;80:175-83.
63. Muntimadugu E, Dhommati R, Jain A, Challa VG, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease. European journal of pharmaceutical sciences. 2016 Sep 20;92:224-34.
64. Karami Z, Zanjani MR, Hamidi M. Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges. Drug discovery today. 2019 May 1;24(5):1104-15.
65. Ferreira LM, Cervi VF, Gehrcke M, da Silveira EF, Azambuja JH, Braganhol E, Sari MH, Zborowski VA, Nogueira CW, Cruz L. Ketoprofen-loaded pomegranate seed oil nanoemulsion stabilized by pullulan: selective antiglioma formulation for intravenous administration. Colloids and Surfaces B: Biointerfaces. 2015 Jun 1;130:272-7.